Injectable axitinib intravitreal implant delivers high drug levels to retinal tissue

Article

The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.

Injectable axitnib intravitreal implant delivers high drug levels to retinal tissue

Erica Kahn and colleagues from Ocular Therapeutix Inc. found both that injection of the axitinib intravitreal implant (OTX-TKI) in non-human primates resulted in high levels of the drug in the retinal tissue and was generally well tolerated.

This intravitreal implant is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.

The advantage of this hydrogel-based implant is that it is designed to deliver the tyrosine kinase inhibitor axitinib to the retinal tissue for from 6 to 9 months, in contrast to current AMD injections that are required every 1 to 2 months for these patients.

In this 9-month study in which the implant was administered to Cynomolgus monkeys, the investigators evaluated the effects of different doses and numbers of implants when the animals received either 3 200-µg- (group 1, n=8), one 300-µg- (group 2, n=8), or one 600-µg- (group 3, n=8) OTX-TKI implant in both eyes on Day 0.

OTX-TKI results

The implant was well tolerated in all groups.

The intraocular pressure did not change significantly and no significant inflammatory response was observed.

The researchers measured high levels of axitinib in the retina tissue at 3 and 6 months after injections in all groups. The drug distributions in the retina and choroid/retinal pigment epithelium were higher in group 1 at 3 months but comparable in all groups at 6 months.

At the 6-month time point, the implants in groups 1 and 2 released about 50% of the drug and in group 3 35% of the drug in the vitreous. The investigators pointed out that the daily release rates in group 1 were higher than in the other groups due to the larger surface area with the three implants used in group 1.

The implants degraded at about month 6 and particles of axitinib particles were seen in the vitreous at month 9. There was minimal drug systemically in the animals in all groups based on the plasma samples obtained at month 3.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.